Successful chemotherapy for gastric cancer with liver metastases
Author Information
Author(s): Takeyama Hiromitsu, Sawai Hirozumi, Wakasugi Takehiro, Takahashi Hiroki, Matsuo Yoichi, Ochi Nobuo, Yasuda Akira, Sato Mikinori, Okada Yuji, Funahashi Hitoshi, Akamo Yoshimi, Manabe Tadao
Primary Institution: Nagoya City University Graduate School of Medical Sciences
Hypothesis
Can combining surgery with chemotherapy improve prognosis in patients with AFP-producing gastric cancer and multiple liver metastases?
Conclusion
Combining surgery with chemotherapy such as paclitaxel may lead to a better prognosis for patients with AFP-producing gastric cancer and multiple liver metastases.
Supporting Evidence
- Initial chemotherapy led to a dramatic decrease in AFP levels and regression of liver metastases.
- After 5 months, new liver metastases appeared, but subsequent treatment again reduced AFP levels and improved liver metastases.
- The patient has maintained a good quality of life and has not experienced progression of liver metastases since treatment.
Takeaway
A 64-year-old man with a rare type of stomach cancer that produces a protein called AFP was treated with surgery and chemotherapy, and he is doing well now.
Methodology
The patient underwent total gastrectomy and received combination chemotherapy with TS-1 and paclitaxel, followed by 5-FU and paclitaxel monotherapy.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
64-year-old Japanese man.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website